骨質疏鬆症藥物市場報告：2030 年趨勢、預測與競爭分析

骨質疏鬆症治療藥物的趨勢與預測

預計到 2030 年，全球骨質疏鬆藥物市場將達到 172 億美元，2024 年至 2030 年年複合成長率為 3.2%。這個市場的主要促進因素是全球骨質疏鬆症發病率的增加和老年人口的增加。全球骨質疏鬆藥物市場前景廣闊，骨質疏鬆原發性和續發性市場都有商機。

。

骨質疏鬆症治療藥物市場洞察

Lucintel 預計 RANKL 抑制劑在預測期內仍將是最大的細分市場，因為擴大採用 RANKL 抑制劑來治療骨折高風險患者的骨質疏鬆症。

由於人口迅速高齡化和消費者對骨質疏鬆症認知的不斷提高，原發性骨質疏鬆症預計將繼續佔據市場的很大一部分。

由於主要參與者的存在、骨質疏鬆症患者數量的增加以及該地區品牌藥物的容易獲得，預計北美在整個預測期內仍將是最大的地區。

本報告回答了 11 個關鍵問題：

• Q.1. 細分市場中最有前途和高成長的機會是什麼？
• Q.2.哪個細分市場將以更快的速度成長？為什麼？
• Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
• Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和業務風險是什麼？
• Q.5. 這個市場的商業風險和競爭威脅是什麼？
• Q.6.這個市場有哪些新趨勢？為什麼？
• Q.7.市場客戶需求有何改變？
• Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
• Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
• Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
• Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球骨質疏鬆藥物市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球骨質疏鬆治療藥物市場趨勢（2018-2023）與預測（2024-2030）
• 按藥物類型分類的全球骨質疏鬆藥物市場
  • 副甲狀腺素治療
  • 雙磷酸鹽
  • 降鈣素
  • RANKL抑制劑
  • 其他
• 全球骨質疏鬆症藥物市場按應用
  • 原發性骨質疏鬆症
  • 續發性骨質疏鬆症

第4章 2018-2030年分地區市場趨勢及預測分析

• 全球骨質疏鬆藥物市場按地區
• 北美骨質疏鬆藥物市場
• 歐洲骨質疏鬆藥物市場
• 亞太骨質疏鬆藥物市場
• 其他地區骨質疏鬆藥物市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球骨質疏鬆症藥物市場成長機會（依藥物類型）
  • 全球骨質疏鬆症藥物市場成長機會（按應用）
  • 全球骨質疏鬆藥物市場按地區成長機會
• 全球骨質疏鬆藥物市場新趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球骨質疏鬆藥物市場的產能
  • 全球骨質疏鬆藥物市場的合併、收購與合資
  • 認證和許可

第7章 主要企業概況

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Osteoporosis Drug Trends and Forecast

The future of the global osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets. The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030 with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.

.

A more than 150-page report is developed to help in your business decisions.

Osteoporosis Drug by Segment

The study includes a forecast for the global osteoporosis drug by drug type, application, and region.

Osteoporosis Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• Rankl Inhibitors
• Others

Osteoporosis Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Primary Osteoporosis
• Secondary Osteoporosis

Osteoporosis Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Osteoporosis Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies osteoporosis drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the osteoporosis drug companies profiled in this report include-

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Osteoporosis Drug Market Insights

Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.

Within this market, primary osteoporosis will remain the larger segment due to surging aging population and growing awareness towards osteoporosis among consumers.

North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.

Features of the Global Osteoporosis Drug Market

Market Size Estimates: Osteoporosis drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Osteoporosis drug market size by drug type, application, and region in terms of value ($B).

Regional Analysis: Osteoporosis drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the osteoporosis drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the osteoporosis drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the osteoporosis drug market size?

Answer: The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030.

Q2. What is the growth forecast for osteoporosis drug market?

Answer: The global osteoporosis drug market is expected to grow with a CAGR of 3.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the osteoporosis drug market?

Answer: The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.

Q4. What are the major segments for osteoporosis drug market?

Answer: The future of the osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets.

Q5. Who are the key osteoporosis drug market companies?

Answer: Some of the key osteoporosis drug companies are as follows:

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Q6. Which osteoporosis drug market segment will be the largest in future?

Answer: Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.

Q7. In osteoporosis drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the osteoporosis drug market by drug type (parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL inhibitors, and others), application (primary osteoporosis and secondary osteoporosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Osteoporosis Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Osteoporosis Drug Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Osteoporosis Drug Market by Drug Type
  • 3.3.1: Parathyroid Hormone Therapy
  • 3.3.2: Bisphosphonates
  • 3.3.3: Calcitonin
  • 3.3.4: RANKL Inhibitors
  • 3.3.5: Others
• 3.4: Global Osteoporosis Drug Market by Application
  • 3.4.1: Primary Osteoporosis
  • 3.4.2: Secondary Osteoporosis

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Osteoporosis Drug Market by Region
• 4.2: North American Osteoporosis Drug Market
  • 4.2.2: North American Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.3: European Osteoporosis Drug Market
  • 4.3.1: European Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.3.2: European Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.4: APAC Osteoporosis Drug Market
  • 4.4.1: APAC Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.4.2: APAC Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.5: ROW Osteoporosis Drug Market
  • 4.5.1: ROW Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.5.2: ROW Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Osteoporosis Drug Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Osteoporosis Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Osteoporosis Drug Market by Region
• 6.2: Emerging Trends in the Global Osteoporosis Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Osteoporosis Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Osteoporosis Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Eli Lily
• 7.3: F. Hoffmann La Roche
• 7.4: Merck
• 7.5: Amgen
• 7.6: Radius Health
• 7.7: Teva Pharmaceutical Industries